- Home
- ZDAI vs CVM Comparison
ZDAI vs CVM Comparison
Compare ZDAI & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | CVM |
|---|---|---|
| Founded | 2022 | 1983 |
| Country | Hong Kong | United States |
| Employees | 33 | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 19.3M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ZDAI | CVM |
|---|---|---|
| Price | $2.20 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 149.7K | ★ 210.2K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.20 | $0.24 |
| 52 Week High | $11.48 | $13.48 |
Technical Indicators
Market Signals| Indicator | ZDAI | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 28.62 |
| Support Level | $0.33 | N/A |
| Resistance Level | $4.10 | $4.84 |
| Average True Range (ATR) | 0.30 | 0.33 |
| MACD | -0.05 | -0.22 |
| Stochastic Oscillator | 29.04 | 8.40 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.